Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 3/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 1/20 | 0.42 |
| ▸ | CDA | P32320 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583331 | 0.86 | TK1 (0.44) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL16099482 | 0.86 | TK1 (0.44) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL15893327 | 0.86 | TK1 (0.44) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL18039264 | 0.85 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL6025793 | 0.85 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL6025787 | 0.85 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL3437046 | 0.85 | LMNA (0.46) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL6889538 | 0.85 | TK1 (0.41) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL4745548 | 0.84 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL12482651 | 0.84 | TK1 (0.45) | LMNASMN1; SMN2ALOX12ADRA1ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118843468-A | Use of hyaluronic acid-nimesulide complexes for the treatment of local late or metastatic tumors | 爱禾公司 | 2024-10-25 | — | — | CN | claimed |
| US-20240050579-A1 | HYALURONAN-NIMESULIDE CONJUGATE FOR TREATING LOCALLY ADVANCED OR METASTATIC TUMORS | AIHOL CORPORATION (US) | 2024-02-15 | — | — | US | claimed |
| WO-2024031050-A2 | HYALURONAN-NIMESULIDE CONJUGATE FOR TREATING LOCALLY ADVANCED OR METASTATIC TUMORS | AIHOL CORPORATION (US) | 2024-02-08 | — | — | WO | claimed |
| EP-2308885-B1 | Novel compounds and methods for therapy | GILEAD SCIENCES INC (US) | 2014-11-19 | — | — | EP | claimed |
| EP-2245037-B1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES INC (US) | 2014-06-18 | — | — | EP | claimed |
| CN-102762215-A | HBV antisense inhibitors | GLAXO GROUP LTD | 2012-10-31 | — | — | CN | claimed |
| EP-2512491-A1 | HBV ANTISENSE INHIBITORS | Glaxo Group Limited (GB) | 2012-10-24 | — | — | EP | claimed |
| WO-2011047312-A1 | HBV ANTISENSE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | WO | claimed |
| EP-2308885-A2 | Novel compounds and methods for therapy | Gilead Sciences, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| CN-102015739-A | Novel compounds and methods for treatment | GILEAD SCIENCES INC | 2011-04-13 | — | — | CN | claimed |
| EP-2245037-A2 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | Gilead Sciences, Inc. (US) | 2010-11-03 | — | — | EP | claimed |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-09-17 | — | — | US | claimed |
| WO-2009105513-A2 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | GILEAD SCIENCES, INC. (US) | 2009-08-27 | — | — | WO | claimed |
| CN-118843468-A | Use of hyaluronic acid-nimesulide complexes for the treatment of local late or metastatic tumors | 爱禾公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11993794-B2 | Methods to create chemically-induced dimerizing protein systems for regulation of cellular events | FRED HUTCHINSON CANCER CENTER (US) | 2024-05-28 | — | — | US | disclosed |
| WO-1996033200-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | ÚSTAV ORGANICKÉ CHEMIE A BIOCHEMIE AKADEMIE VED C^¿ESKÉ REPUBLIKY (CZ) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050579-A1 | HYALURONAN-NIMESULIDE CONJUGATE FOR TREATING LOCALLY ADVANCED OR METASTATIC TUMORS | CD44, TYMP, NME1 | LMNA 1999/4885SMN1; SMN2 818/4885ALOX12 2121/4885 |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | LMNA 3658/4885SMN1; SMN2 3549/4885ALOX12 2229/4885 |
| US-20090232768-A1 | NOVEL COMPOUNDS AND METHODS FOR THERAPY | TP53, ZC3HAV1, ZFX | LMNA 2397/4885SMN1; SMN2 951/4885ALOX12 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.